N,N'''-1,2-ETHANEDIYLBIS[N-[3-[[4,6-BIS[BUTYL(1,2,2,6,6-PENTAMETHYL-4-PIPERIDINYL)AMINO]-1,3,5-TRIAZIN-2-YL]AMINO]PROPYL]-N',N''-DIBUTYL-N',N''-BIS(1,2,2,6,6-PENTAMETHYL-4-PIPERIDINYL)-1,3,5-TRIAZINE-2,4,6-DIAMINE
General Information
| Mainterm | N,N'''-1,2-ETHANEDIYLBIS[N-[3-[[4,6-BIS[BUTYL(1,2,2,6,6-PENTAMETHYL-4-PIPERIDINYL)AMINO]-1,3,5-TRIAZIN-2-YL]AMINO]PROPYL]-N',N''-DIBUTYL-N',N''-BIS(1,2,2,6,6-PENTAMETHYL-4-PIPERIDINYL)-1,3,5-TRIAZINE-2,4,6-DIAMINE |
| CAS Reg.No.(or other ID) | 106990-43-6 |
| Regnum |
178.2010 |
From www.fda.gov
Computed Descriptors
Download SDF| 2D Structure | |
| CID | 163763 |
| IUPAC Name | 6-N-[3-[[4,6-bis[butyl-(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl]-[2-[[4,6-bis[butyl-(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl]-[3-[[4,6-bis[butyl-(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl]amino]propyl]amino]ethyl]amino]propyl]-2-N,4-N-dibutyl-2-N,4-N-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4,6-triamine |
| InChI | InChI=1S/C132H250N32/c1-49-57-71-157(97-81-117(9,10)147(41)118(11,12)82-97)109-135-105(136-110(143-109)158(72-58-50-2)98-83-119(13,14)148(42)120(15,16)84-98)133-67-65-69-155(107-139-113(161(75-61-53-5)101-89-125(25,26)151(45)126(27,28)90-101)145-114(140-107)162(76-62-54-6)102-91-127(29,30)152(46)128(31,32)92-102)79-80-156(108-141-115(163(77-63-55-7)103-93-129(33,34)153(47)130(35,36)94-103)146-116(142-108)164(78-64-56-8)104-95-131(37,38)154(48)132(39,40)96-104)70-66-68-134-106-137-111(159(73-59-51-3)99-85-121(17,18)149(43)122(19,20)86-99)144-112(138-106)160(74-60-52-4)100-87-123(21,22)150(44)124(23,24)88-100/h97-104H,49-96H2,1-48H3,(H,133,135,136,143)(H,134,137,138,144) |
| InChI Key | OWXXKGVQBCBSFJ-UHFFFAOYSA-N |
| Canonical SMILES | CCCCN(C1CC(N(C(C1)(C)C)C)(C)C)C2=NC(=NC(=N2)NCCCN(CCN(CCCNC3=NC(=NC(=N3)N(CCCC)C4CC(N(C(C4)(C)C)C)(C)C)N(CCCC)C5CC(N(C(C5)(C)C)C)(C)C)C6=NC(=NC(=N6)N(CCCC)C7CC(N(C(C7)(C)C)C)(C)C)N(CCCC)C8CC(N(C(C8)(C)C)C)(C)C)C9=NC(=NC(=N9)N(CCCC)C1CC(N(C(C1)(C)C)C)(C)C)N(CCCC)C1CC(N(C(C1)(C)C)C)(C)C)N(CCCC)C1CC(N(C(C1)(C)C)C)(C)C |
| Molecular Formula | C132H250N32 |
| Wikipedia | antioxidant 119 |
From Pubchem
Computed Properties
| Property Name | Property Value |
|---|---|
| Molecular Weight | 2285.676 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 32 |
| Rotatable Bond Count | 55 |
| Complexity | 3790.0 |
| CACTVS Substructure Key Fingerprint | A A A D c f B / w A A A A A A A A A A A A A A A A A A A A A A A A A A s W L F i w A A A A A A B / g A A H A A Q A A A A D K j B A A Q D E A f I E A A g A A A A J A A A A A k A A I A B A I A I A A C A S A I A y A A U A A A I E A K A A A E Q g E A M A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = = |
| Topological Polar Surface Area | 237.0 |
| Monoisotopic Mass | 2284.055 |
| Exact Mass | 2285.058 |
| XLogP3 | None |
| XLogP3-AA | 29.8 |
| Compound Is Canonicalized | True |
| Formal Charge | 0 |
| Heavy Atom Count | 164 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Isotope Atom Count | 0 |
| Covalently-Bonded Unit Count | 1 |
From Pubchem
ADMET Predicted Profile --- Classification
| Model | Result | Probability |
|---|---|---|
| Absorption | ||
| Blood-Brain Barrier | BBB- | 0.5342 |
| Human Intestinal Absorption | HIA+ | 0.9957 |
| Caco-2 Permeability | Caco2+ | 0.5145 |
| P-glycoprotein Substrate | Substrate | 0.8927 |
| P-glycoprotein Inhibitor | Inhibitor | 0.7194 |
| Non-inhibitor | 0.6327 | |
| Renal Organic Cation Transporter | Inhibitor | 0.5067 |
| Distribution | ||
| Subcellular localization | Lysosome | 0.7600 |
| Metabolism | ||
| CYP450 2C9 Substrate | Non-substrate | 0.8858 |
| CYP450 2D6 Substrate | Non-substrate | 0.7216 |
| CYP450 3A4 Substrate | Substrate | 0.5368 |
| CYP450 1A2 Inhibitor | Non-inhibitor | 0.7726 |
| CYP450 2C9 Inhibitor | Non-inhibitor | 0.8842 |
| CYP450 2D6 Inhibitor | Inhibitor | 0.5160 |
| CYP450 2C19 Inhibitor | Non-inhibitor | 0.8650 |
| CYP450 3A4 Inhibitor | Non-inhibitor | 0.8444 |
| CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.9326 |
| Excretion | ||
| Toxicity | ||
| Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.6237 |
| Inhibitor | 0.8450 | |
| AMES Toxicity | Non AMES toxic | 0.7309 |
| Carcinogens | Non-carcinogens | 0.8941 |
| Fish Toxicity | High FHMT | 0.9287 |
| Tetrahymena Pyriformis Toxicity | High TPT | 0.9832 |
| Honey Bee Toxicity | Low HBT | 0.8330 |
| Biodegradation | Not ready biodegradable | 0.9935 |
| Acute Oral Toxicity | III | 0.7523 |
| Carcinogenicity (Three-class) | Non-required | 0.5829 |
From admetSAR
ADMET Predicted Profile --- Regression
| Model | Value | Unit |
|---|---|---|
| Absorption | ||
| Aqueous solubility | -3.3457 | LogS |
| Caco-2 Permeability | 0.9313 | LogPapp, cm/s |
| Distribution | ||
| Metabolism | ||
| Excretion | ||
| Toxicity | ||
| Rat Acute Toxicity | 2.5553 | LD50, mol/kg |
| Fish Toxicity | 1.5412 | pLC50, mg/L |
| Tetrahymena Pyriformis Toxicity | 0.5952 | pIGC50, ug/L |
From admetSAR
Taxonomic Classification
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic nitrogen compounds |
| Class | Organonitrogen compounds |
| Subclass | Amines |
| Intermediate Tree Nodes | Tertiary amines - Tertiary alkylarylamines |
| Direct Parent | Dialkylarylamines |
| Alternative Parents | |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | Dialkylarylamine - Amino-1,3,5-triazine - Aminotriazine - Secondary aliphatic/aromatic amine - N-aliphatic s-triazine - Piperidine - Triazine - 1,3,5-triazine - Heteroaromatic compound - Tertiary aliphatic amine - Organoheterocyclic compound - Secondary amine - Azacycle - Organopnictogen compound - Hydrocarbon derivative - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group. |
From ClassyFire